---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-016387"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:17:48.864135+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Glucotrack reports positive final first-in-human CBGM study results with MARD 7.7%

## Summary
- Study met all endpoints; MARD 7.7% across 122 matched pairs, 99% data capture, no serious adverse events.
- 92% of readings in green zone of Diabetes Technology Society Error Grid, none in unsafe zones.
- Ten participants with Type 1 or Type 2 diabetes; device implanted via subclavian vein, monitored 4 days.
- Glucotrack expects to initiate long-term early feasibility study in Q3 2025.
- OneTwo Analytics applied AI/ML analytics to validate performance.

## SEC filing metadata
- accession: 0001641172-25-016387
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000164117225016387/0001641172-25-016387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000164117225016387/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-016387
- JSON: https://secwatch.observer/filing/0001641172-25-016387.json
- Plain text: https://secwatch.observer/filing/0001641172-25-016387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.